期刊文献+

中性粒细胞/淋巴细胞比值对多发性骨髓瘤患者的预后评估价值 被引量:12

The prognostic value of neutrophil/lymphocyte ratio in patients with multiple myeloma
在线阅读 下载PDF
导出
摘要 目的探讨外周血中性粒细胞/淋巴细胞比值(NLR)在多发性骨髓瘤(MM)患者预后中的价值。方法回顾性分析87例初诊MM患者和100例体检健康者临床资料,将MM患者以NLR平均值为临界值分为低NLR组(NLR<2.68)和高NLR组(NLR≥2.68),分析2组性别、年龄、国际分期体系(ISS)、总体生存期、实验室检查结果等资料的差异,通过Kaplan-Meier法和Cox比例风险回归模型做单因素和多因素分析,确定影响MM患者的预后因素。结果MM组的NLR值明显高于健康对照组(t=2.21,P<0.05)。与低NLR组比较,高NLR组血清β2-微球蛋白(β2-MG)、钙、肌酐水平偏高,差异有统计学意义(P<0.05)。高NLR组较低NLR组总体生存期短、5年生存率低。单因素分析和多因素分析结果显示,NLR≥2.68,β2-MG升高是MM预后不良的危险因素及独立危险因素(P<0.05)。结论NLR是MM患者预后判断的1个独立危险因素,高水平NLR患者的总体生存期短,但需大样本资料证实。 Objective To investigate the prognostic value of peripheral blood neutrophil/lymphocyte ratio(NLR)in patients with multiple myeloma(MM).Methods The clinical data of 87 newly diagnosed MM patients and 100 healthy people were analyzed retrospectively.MM patients were divided into low NLR group(NLR<2.68)and high NLR group(NLR≥2.68)with the mean value of NLR as the critical value.The differences of sex,age,internation staging system(ISS),overall survival period and laboratory examination results between the two groups were analyzed,Kaplan-Meier method and Cox proportional risk regression model were used for single factor and multi factor analysis to determine the prognostic factors of MM patients.Results The NLR value of the MM group was significantly higher than that of the healthy control group(t=2.21,P<0.05).Compared with the low NLR group,the serumβ2-microglobulin(β2-MG),calcium and creatinine levels of the high NLR group were significantly higher(P<0.05).The high NLR group and the lower NLR group had a short overall survival and a low 5 year survival rate.Univariate analysis and multivariate analysis showed that NLR≥2.68,and elevatedβ2-MG were adverse risk factors and independent risk factors for MM prognosis(P<0.05).Conclusion NLR is an independent risk factor for the prognosis of MM patients.The overall survival of patients with high-level NLR is short,but large sample data is needed to confirm it.
作者 刘红春 黄国虹 崔彦杰 贾海英 王昌敏 LIU Hongchun;HUANG Guohong;CUI Yanjie;JIA Haiying;WANG Changmin(Center of Clinical Laboratory,People′s Hospital of Xinjiang Uygur Autonomous Region,Urumqi,Xinjiang 830001,China)
出处 《国际检验医学杂志》 CAS 2020年第10期1203-1205,1209,共4页 International Journal of Laboratory Medicine
基金 新疆维吾尔自治区自然科学基金项目(2016D01C106)。
关键词 多发性骨髓瘤 中性粒细胞/淋巴细胞比值 预后 multiple myeloma neutrophil/lymphocyte ratio prognosis
  • 相关文献

参考文献7

二级参考文献81

  • 1Brenner H, Gondos A, Pulte D. term survival of younger patients Recent major improvement in long- with multiple myeloma [J]. Blood, 2008, 111: 2521-2526.
  • 2Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005, 55: 74-108.
  • 3Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012[J]. CACancer J Clin, 2012, 62: 10-29.
  • 4Sonneveld P, Schmidt-Wolf I, van der Holt B, et al. HOVON- 65/GMMG-HD4 randomized phase HI trial comparing bortezomib, doxorubicin, dexamethasone (PAD) Vs VAD followed by high-dose melphalan (HI)M) and maintenance with bortezomib or thalidomide iIn patients with newly diagnosed multiple myeloma (MM)[J]. ASH Annual Meeting Abstracts, 2010, 116: 40.
  • 5Rosino| L, Cibeira MT, Mateos MV, et al. Phase 1~ PETHEMA/GEM study of induction therapy prior autologous stem cell transplantation (ASCT) in multiple myeloma: superiority of VTD (bortezomib/thalidomide/dexamethasone) over TD and VBMCP/VBAD plus bortezomib[J]. ASH Annual Meeting Abstracts, 2010, 116: 307.
  • 6Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma[J]. Blood, 2012, 119: 4375-4382.
  • 7Rajkumar S, Blood EA, Vesole D, et al. Phase Ill clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group[J]. J Clin Oncol, 2006, 24: 431-436.
  • 8Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma [J]. J Clin Onco], 2005, 23 ( 15 ): 3412-3420.
  • 9Dimopoulos MA, Kastritis E, Michalis E, et al. The International Scoring System (1SS) tbr multiple myeloma remains a robust prognostic tool independently of patients' renal function [J]. Ann Oncol, 2012, 23(3 ): 722-729.
  • 10Dimopoulos MA, Tcrpos E, Chanan-Khan A, et al. Renal impair- ment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group [J ]. J Clin Oncol, 2010, 28( 33 ):4976-4984.

共引文献53

同被引文献128

引证文献12

二级引证文献80

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部